MatthewFuryMD

Oncology • Thornwood, NY

Head & Neck Cancer

Senior Director, Oncology Clinical Sciences, Regeneron Pharmaceuticals

Join to view full profile

Dr. Fury is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Fury's full profile

Already have an account?

Office
777 Old Saw Mill River Road, Tarrytown, NY
Thornwood, NY 10594
Is this information wrong?

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2003 - 2006
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2000 - 2003
State University of New York Downstate Medical Center College of MedicineClass of 2000

Certifications & Licensure

NY State Medical License 2002 - 2025

Clinical Trials

Cisplatin and Everolimus in Treating Patients With Advanced Solid Tumors Start of enrollment: 2006 Nov 01
Completed
Phase 1
Cisplatin, Bevacizumab, and Intensity-Modulated Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer Start of enrollment: 2006 Oct 01
Completed
Phase 2
Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Start of enrollment: 2007 Jul 01
Completed
Phase 2
Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer Start of enrollment: 2007 Nov 01
Completed
Phase 2
Docetaxel + Cetuximab + Concurrent Re-Irradiation (Intensity - Modulated Radiation Therapy, IMRT) for Patients With Locoregionally Recurrent Head and Neck Cancer Start of enrollment: 2008 Jul 01
Completed
Phase 2
Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC) Start of enrollment: 2008 Aug 01
Completed
Phase 1
Radiation Therapy (IMRT) + RAD001 (Everolimus) + Cisplatin for Patients With Head and Neck Cancer Start of enrollment: 2009 Mar 01
Completed
Phase 1
RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer Start of enrollment: 2009 Jul 01
Completed
Phase 1
Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma Start of enrollment: 2009 Aug 01
Completed
Phase 2
Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC) Start of enrollment: 2009 Nov 01
Completed
Phase 1, Phase 2
Pharmacodynamic Effects of Ribavirin in Patients With Tonsil and/or Base of Tongue Squamous Cell Carcinoma Start of enrollment: 2010 Dec 28
Completed
Not Applicable
BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors Start of enrollment: 2011 Feb 15
Completed
Phase 1
A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2012 Nov 12
Terminated
Phase 1, Phase 2
Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC) Start of enrollment: 2012 Nov 01
Completed
Phase 1
Phase 1b Trial of BGJ398/BYL719 in Solid Tumors Start of enrollment: 2013 Oct 01
Completed
Phase 1
Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors Start of enrollment: 2014 May 14
Completed
Phase 1
Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies Start of enrollment: 2014 Aug 07
Terminated
Phase 1
Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy Start of enrollment: 2014 Jul 28
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

10 citations
EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer.
Ana Oaknin, Bradley J Monk, Ignace Vergote, Andreia Cristina de Melo, Yong-Man Kim, Alla S Lisyanskaya, Vanessa Samouëlian, Hee Seung Kim, Evgeniy A Gotovkin, Fernanda...> ;European Journal of Cancer. 2022 Oct 1
2 citations
Hedgehog pathway inhibitor real-world treatment patterns in patients with basal cell carcinoma: a claims-based analysis.
Wenzhen Ge, Chieh-I Chen, Ning Wu, Matthew G Fury, Emily Ruiz, Jessica J Jalbert> ;Future Oncology. 2022 Jul 1
3 citations
Pharmacodynamic and therapeutic pilot studies of single-agent ribavirin in patients with human papillomavirus-related malignancies.
Bharat Burman, Scott B Drutman, Matthew G Fury, Richard J Wong, Nora Katabi, Alan L Ho, David G Pfister> ;Oral Oncology. 2022 May 1
12 citations
Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage Colony-Stimulating Factor in Patients with Recurrent or Metastatic Head and Nec...
Hani M. Babiker, Irene Brana, Daruka Mahadevan, Taofeek K. Owonikoko, Emiliano Calvo, Danny Rischin, Victor Moreno, Kyriakos P. Papadopoulos, Marka R. Crittenden, Silv...> ;The Oncologist. 2021 Sep 1
45 citations
Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis.
Danny Rischin, Nikhil I. Khushalani, Chrysalyne D. Schmults, Alexander Guminski, Anne Lynn S. Chang, Karl D. Lewis, Annette M. Lim, Leonel Hernandez-Aya, Brett G.M. Hu...> ;Journal for Immunotherapy of Cancer. 2021 Aug 1
129 citations
Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial
Alexander J. Stratigos, Aleksandar Sekulic, Ketty Peris, Oliver Bechter, Sorilla Prey, Martin Kaatz, Karl D. Lewis, Nicole Basset-Seguin, Anne Lynn S. Chang, Stéphane ...> ;The Lancet. Oncology. 2021 Jun 1
7 citations
Fixed Dose of Cemiplimab in Patients with Advanced Malignancies Based on Population Pharmacokinetic Analysis.
Anne Paccaly, Michael R. Migden, Kyriakos P. Papadopoulos, Feng Yang, John D. Davis, Ronda Rippley, Israel Lowy, Matthew G. Fury, Elizabeth Stankevich, Danny Rischin> ;Advances in Therapy. 2021 Mar 25
9 citations
Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): Data fr...
Victor Moreno, Pilar Garrido, Kyriakos P. Papadopoulos, Maria Jose De Miguel Luken, Marta Gil-Martin, Raid Aljumaily, Lee S. Rosen, P. Rietschel, Kosalai Kal Mohan, Su...> ;Lung Cancer. 2021 May 1
37 citations
OncoTree: A Cancer Classification System for Precision Oncology.
Ritika Kundra, Hongxin Zhang, Robert L. Sheridan, Sahussapont Joseph Sirintrapun, Avery Wang, Angelica Ochoa, Manda Wilson, Benjamin Gross, Yichao Sun, Ramyasree Madup...> ;JCO Clinical Cancer Informatics. 2021 Feb 1
33 citations
Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma.
Sam Keeping, Yingxin Xu, Chieh-I Chen, Shannon Cope, Ali Mojebi, Andreas Kuznik, Gerasimos Konidaris, Dieter Ayers, Medha Sasane, Rachel Allen, Thi-Minh-Thao Huynh, Ev...> ;Future Oncology. 2021 Feb 1
46 citations
PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer
Danny Rischin, Marta Gil-Martin, Antonio González-Martín, Irene Brana, June Y. Hou, Daniel Cho, Gerald Steven Falchook, Silvia C. Formenti, Salma K. Jabbour, Kathleen ...> ;Gynecologic Oncology. 2020 Nov 1
33 citations
Clinical outcomes among unresectable, locally advanced, and metastatic cutaneous squamous cell carcinoma patients treated with systemic therapy
C. Lance Cowey, Nicholas J. Robert, Janet L. Espirito, Kalatu Davies, Jennifer Frytak, Israel Lowy, Matthew G. Fury> ;Cancer Medicine. 2020 Jun 24
98 citations
Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing
Danny Rischin, Michael R. Migden, Annette M. Lim, Chrysalyne D. Schmults, Nikhil I. Khushalani, Brett G.M. Hughes, Dirk Schadendorf, Lara Dunn, Leonel Hernandez-Aya, A...> ;Journal for Immunotherapy of Cancer. 2020 Jun 1
41 citations
First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low Dose Cyclophosphamide in Patients with Advanced Malignancies.
Kyriakos P. Papadopoulos, Melissa Lynne Johnson, Albert C. Lockhart, Kathleen N. Moore, Gerald Steven Falchook, Silvia C. Formenti, Aung Naing, Richard D. Carvajal, Le...> ;Clinical Cancer Research. 2020 Mar 1
37 citations
A Phase 1b Study of Cetuximab and BYL719 (Alpelisib) Concurrent with Intensity Modulated Radiation Therapy in Stage III-IVB Head and Neck Squamous Cell Carcinoma.
Lara Dunn, Nadeem Riaz, Matthew G. Fury, Sean McBride, Loren S. Michel, Nancy Y. Lee, Eric J. Sherman, Shrujal S. Baxi, Sofia Haque, Nora Katabi, Richard J. Wong, Han ...> ;International Journal of Radiation Oncology, Biology, Physics. 2020 Mar 1
246 citations
Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial.
Michael R. Migden, Nikhil I. Khushalani, Anne Lynn S. Chang, Karl D. Lewis, Chrysalyne D. Schmults, Leonel Hernandez-Aya, Friedegund Meier, Dirk Schadendorf, Alexander...> ;The Lancet. Oncology. 2020 Feb 1
17 citations
MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer.
Ofra Novoplansky, Matthew G. Fury, Manu Prasad, Ksenia M. Yegodayev, Jonathan Zorea, Limor Cohen, Raphael Pelossof, Liz Cohen, Nora Katabi, Fabiola Cecchi, Ben-Zion Jo...> ;International Journal of Cancer. 2019 Aug 1
61 citations
Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort.
Neil H. Segal, Sai-Hong Ignatius Ou, Ani Sarkis Balmanoukian, Matthew G. Fury, Erminia Massarelli, Julie R. Brahmer, Jared Weiss, Patrick Schöffski, Scott J. Antonia, ...> ;European Journal of Cancer. 2019 Mar 1
795 citations
PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma
Michael R. Migden, Danny Rischin, Chrysalyne D. Schmults, Alexander Guminski, Axel Hauschild, Karl D. Lewis, Christine H. Chung, Leonel Hernandez-Aya, Annette M. Lim, ...> ;The New England Journal of Medicine. 2018 Jun 4
47 citations
Anti‐Hu‐Associated Autoimmune Limbic Encephalitis in a Patient with PD‐1 Inhibitor‐Responsive Myxoid Chondrosarcoma
Kyriakos P. Papadopoulos, Rebecca Romero, Gabriela Gonzalez, James E. Dix, Israel Lowy, Matthew G. Fury> ;The Oncologist. 2018 Jan 1
27 citations
Phase I study of induction chemotherapy with afatinib, ribavirin, and weekly carboplatin and paclitaxel for stage IVA/IVB human papillomavirus-associated oropharyngeal...
Lara Dunn, Matthew G. Fury, Eric J. Sherman, Alan A. Ho, Nora Katabi, Sofia Haque, David G. Pfister> ;Head & Neck. 2018 Feb 1
55 citations
Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer.
Eric J. Sherman, Lara Dunn, Alan L. Ho, Shrujal S. Baxi, Ronald Ghossein, Matthew G. Fury, Sofia Haque, Grace Cullen, James A. Fagin, David G. Pfister> ;Cancer. 2017 Nov 1
10 citations
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensifie...
Lillian M. Smyth, Kelsey R. Monson, Komal Jhaveri, Alexander Drilon, Bob T. Li, Wassim Abida, Gopa Iyer, John F. Gerecitano, Mrinal M. Gounder, James J. Harding, Marti...> ;Investigational New Drugs. 2017 Mar 9
97 citations
Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810
Gerald Steven Falchook, Rom Leidner, Elizabeth Stankevich, Brian D. Piening, Carlo Bifulco, Israel Lowy, Matthew G. Fury> ;Journal for Immunotherapy of Cancer. 2016 Nov 15
62 citations
A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma
Alan Loh Ho, Lara Dunn, Eric J. Sherman, Matthew G. Fury, Shrujal S. Baxi, Raghu Chandramohan, Snjezana Dogan, Luc G. T. Morris, Grace Cullen, Sofia Haque, Camelia Sim...> ;Annals of Oncology. 2016 Oct 1
Join now to see all

Hospital Affiliations

Memorial Sloan Kettering Cancer CenterNew York, New York